Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea)

[1]  R. Whitbourn,et al.  Renal Denervation in High-Risk Patients With Hypertension. , 2020, Journal of the American College of Cardiology.

[2]  K. Kario,et al.  Renal Denervation in Asia , 2020, HYPERTENSION.

[3]  Yen-Wen Wu,et al.  Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan). , 2019, Acta Cardiologica Sinica.

[4]  Yen-Hung Lin,et al.  2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension. , 2019, Acta Cardiologica Sinica.

[5]  G. Mancia,et al.  Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry , 2019, European heart journal.

[6]  K. Kario,et al.  Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan　- Safety and Efficacy of Renal Denervation at 3 Years. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[7]  Fahad Khan,et al.  Catheter-Based Renal Denervation in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED): A Randomised, Sham-Controlled, Proof-of-Concept Trial , 2018 .

[8]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[9]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[10]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[11]  J. Osborn,et al.  Catheter-Based Renal Nerve Ablation as a Novel Hypertension Therapy: Lost, and Then Found, in Translation. , 2018, Hypertension.

[12]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[13]  Wilbert S Aronow,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[14]  I. D. de Boer,et al.  Diabetes and Hypertension: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.

[15]  J. Osborn,et al.  Renal Nerves and Long-Term Control of Arterial Pressure. , 2017, Comprehensive Physiology.

[16]  E. Grossman,et al.  Blood pressure control in type 2 diabetic patients , 2017, Cardiovascular Diabetology.

[17]  Deepak L. Bhatt,et al.  The Present and FutureReview Topic of the WeekRegression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials , 2016 .

[18]  C. Kim,et al.  Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea) , 2016, Journal of Human Hypertension.

[19]  G. Teng,et al.  Renal Denervation , 2015, Medicine.

[20]  R. Whitbourn,et al.  First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension , 2015, Hypertension.

[21]  E. Vink,et al.  Denervation of the Renal Arteries in Metabolic Syndrome: The DREAMS-Study , 2015, Hypertension.

[22]  H. Krum,et al.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. , 2014, European heart journal.

[23]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[24]  V. Somers,et al.  Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea , 2011, Hypertension.

[25]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[26]  Michael Böhm,et al.  Renal denervation: a potential new treatment modality for polycystic ovary syndrome? , 2011, Journal of hypertension.

[27]  G. Tognoni,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association , 2007, Diabetes Care.

[28]  R. Bilous,et al.  Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study , 2001, BMJ : British Medical Journal.

[29]  P. Brink,et al.  Renal Denervation in High-risk Patients with Hypertension. , 2019, Heart international.

[30]  K. Kario.  PREFACE: Is Renal Denervation Effective Option for Management of Hypertension in Asia? , 2017, Current hypertension reviews.

[31]  R. Eckel,et al.  Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes , 2007 .